CN104873880A - Traditional Chinese medicine for treating chronic atrophic gastritis precancerous lesions - Google Patents
Traditional Chinese medicine for treating chronic atrophic gastritis precancerous lesions Download PDFInfo
- Publication number
- CN104873880A CN104873880A CN201510358811.3A CN201510358811A CN104873880A CN 104873880 A CN104873880 A CN 104873880A CN 201510358811 A CN201510358811 A CN 201510358811A CN 104873880 A CN104873880 A CN 104873880A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- atrophic gastritis
- traditional chinese
- rhizoma atractylodis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of the medical technology, and particularly relates to traditional Chinese medicine for treating chronic atrophic gastritis precancerous lesions. The traditional Chinese medicine includes the following traditional Chinese medicine bulk drugs of, by weight, 11-19 parts of dandelions, 11-19 parts of Chinese violets, 4-8 parts of edible tulips, 8-16 parts of scutellaria baicalensis, 8-16 parts of cortex phellodendri, 8-16 parts of yam rhizomes, 11-19 parts of hypericum japonicum, 8-16 parts of alpinia katsumadai, 8-16 parts of fructus amomi, 5-13 parts of amomum tsaoko, 8-16 parts of rhizoma atractylodis, 8-16 parts of atractylodes macrocephala koidz, 1-3 parts of leeches, 1-3 parts of gadflies and 4-8 parts of liquorice. The traditional Chinese medicine can relieve gastric mucosa hyperemia, hydroncus and erosion of patients and relieve the gastroscope symptoms such as mucosa whitening and grain growth, and the cure rate of the precancerous lesion pathology of the patients is increased.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of Chinese medicine for the treatment of precancerous lesions of chronic atrophic gastritis.
Background technology
Chronic atrophic gastritis (CAG) is a type of chronic gastritis, means that gastric epithelial suffers repeatedly to damage the minimizing causing intrinsic body of gland, companion or do not accompany that fiber substitutes, the chronic disease of stomach of one of intestinal gland metaplasia and/or Pseudopyloric gland metaplasia.Current Chinese scholars thinks that the last such process of gastric cancer of normal gastric mucosa, secondly chronic atrophic gastritis, again intestinal epithelial metaplasia and then atypical hyperplasia (intraepithelial neoplasia) is followed in gastric mucosa generation canceration mostly.Therefore, by Drug therapy, block precancerous lesion to further develop or reverse its pathological change quite crucial.Also not yet there is the medicine being exclusively used in treatment precancerous lesions of chronic atrophic gastritis at present.
Summary of the invention
Technical problem to be solved by this invention avoids the weak point existing for above-mentioned prior art, a kind of Chinese medicine for the treatment of precancerous lesions of chronic atrophic gastritis is provided, this Chinese medicine can alleviate patient's gastric mucosa congestion, edema, erosion, alleviate the gastroscope signs such as the white phase of mucosa, grain growth, improve the cure rate of patient's precancerous lesion pathology.
The present invention is achieved through the following technical solutions:
Treat a Chinese medicine for precancerous lesions of chronic atrophic gastritis, be made up of the raw material of Chinese medicine medicine of following weight portion:
Herba Taraxaci 11-19 part, Herba Violae 11-19 part, Pseudobulbus Cremastrae Seu Pleiones 4-8 part, Radix Scutellariae 8-16 part, Cortex Phellodendri 8-16 part, Rhizoma Dioscoreae Septemlobae 8-16 part, Herba Hyperici Japonici 11-19 part, Semen Alpiniae Katsumadai 8-16 part, Fructus Amomi 8-16 part, Fructus Tsaoko 5-13 part, Rhizoma Atractylodis 8-16 part, Rhizoma Atractylodis Macrocephalae 8-16 part, Hirudo 1-3 part, Tabanus 1-3 part, Radix Glycyrrhizae 4-8 part.
Preferably, the Chinese medicine of above-mentioned treatment precancerous lesions of chronic atrophic gastritis, be made up of the raw material of Chinese medicine medicine of following weight portion:
Herba Taraxaci 13-17 part, Herba Violae 13-17 part, Pseudobulbus Cremastrae Seu Pleiones 5-7 part, Radix Scutellariae 10-14 part, Cortex Phellodendri 10-14 part, Rhizoma Dioscoreae Septemlobae 10-14 part, Herba Hyperici Japonici 13-17 part, Semen Alpiniae Katsumadai 10-14 part, Fructus Amomi 10-14 part, Fructus Tsaoko 7-11 part, Rhizoma Atractylodis 10-14 part, Rhizoma Atractylodis Macrocephalae 10-14 part, Hirudo 1.5-2.5 part, Tabanus 1.5-2.5 part, Radix Glycyrrhizae 5-7 part.
Preferred, the Chinese medicine of above-mentioned treatment precancerous lesions of chronic atrophic gastritis, be made up of the raw material of Chinese medicine medicine of following weight portion:
Herba Taraxaci 15 parts, Herba Violae 15 parts, Pseudobulbus Cremastrae Seu Pleiones 6 parts, Radix Scutellariae 12 parts, Cortex Phellodendri 12 parts of, Rhizoma Dioscoreae Septemlobae 12 parts, Herba Hyperici Japonici 15 parts, Semen Alpiniae Katsumadai 12 parts, Fructus Amomi 12 parts, Fructus Tsaoko 9 parts, Rhizoma Atractylodis 12 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, Hirudo 2 parts, Tabanus 2 parts, 6 parts, Radix Glycyrrhizae.
The ratio of above weight proportion is through that science screening obtains, and for especial patient, as serious symptom or mild, fat or modest patient, can the proportioning of amount of corresponding adjustment composition, and increase or reduce being no more than 100%, drug effect is substantially constant.
The weight portion of said medicine, if in units of g, the normally consumption of 1 dose.
The indication of Chinese medicine of the present invention: be used for the treatment of precancerous lesions of chronic atrophic gastritis.
The taboo item of Chinese medicine of the present invention: the fasting for the treatment of period in a medicine is greasy, raw and cold, the smelling of fish or mutton, irritant and stodgy food.
Clinically chronic atrophic gastritis with gastral cavilty portion pain, glutted, painful abdominal mass is vexed, belch, indigestion and loss of appetite etc. be main manifestations person, belong to the disease category such as the traditional Chinese medical science " gastric abscess ", " feeling of fullness ", " stomach painful abdominal mass ", " stuffy sensation of deftciency type ", " noisy ".Inventor is on the basis of inheriting forefathers' theory, in the clinical practice for the treatment of chronic atrophic gastritis, sum up " turbid poison " theory, and be applied to the treatment of chronic atrophic gastritis, and prevent and treat chronic atrophic gastritis companion's intestinal epithelial metaplasia and atypical hyperplasia (intraepithelial neoplasia) with " turbid poison " argument, think that chronic atrophic gastritis companion precancerous lesion patient major part is for accumulateing in turbid poison, stomach network stasis blocking is demonstrate,proved.No matter turbid pathogen is by entering outward, and turbid damp is stranded spleen, or eating and drinking without temperance, and feelings will is not relaxed, raw in turbid pathogen, dysfunction of the spleen in transportation; Still, in intimately accumulateing, lie prostrate in blood system as malicious; Or accumulate in turbid pathogen, hot and suffocating is poison; All with dysfunction of the spleen in transportation the lucid yang sending up, stomach-QI being unable to descend normally is in close relations.Spleen is lunar wet soil, likes dry evil and wets, easily by damp is stranded; Stomach is the bright dry soil of sun, and the wet evil of happiness is dry, easily by pathogenic heat is disturbed; Turbid for wet gradually, poison is burning hot pole, so Jiao in taste easily invaded by turbid poison.Spleen is transporting not, essence of water and grain cannot on be attributed to lung, lower defeated bladder, clearing heat in QI system can not the defeated cloth whole body, and the metabolism of water liquid is not normal, with the passing of time change raw for water turbid damp evil.Temper the lucid yang sending up is the result of transporting and transforming function of the spleen and stomach, the dysfunction of the spleen, then clear YANG failing to ascend, and vigour can not obtain the abundance of clearing heat in QI system, and function fails; Stomach-QI being unable to descend normally, not only can not be received and digesting food, and small intestinal also cannot be made to carry out separating the useful from the waste and large intestine transporting waste, and gastrointestinal deficiency and excess is difficult to substitute, transporting and fall not normal, raw in turbid poison.In addition turbid poison pents up retardance meridians, and qi-blood-body fluid is run defeated cloth and hindered, and is jammed in zang-fu differentiation, and mechanism of qi can not be unobstructed; Accumulate in turbid poison in body, taste abnormal ascending-descending of QI, mechanism of qi cannot ascending, descending, exiting and entering.Pathogen like this must not be fallen apart, depression and stagnation of QI, Tianjin stasis, adds deep poison with the passing of time further.Repeatedly, the state of an illness constantly increases the weight of in vicious cycle like this.Visible taste the Emergence and Development of turbid poison and pathogenic links relation inseparable.The sick position of primary disease is at stomach, closely related with liver spleen, and accumulate in turbid poison and stop up the key that stagnant middle Jiao is primary disease pathogenesis, stomach network stasis blocking is also its key pathological link.Therefore, accumulate in turbid poison, pathogenesis that stomach network stasis blocking is precancerous lesions of chronic atrophic gastritis.Need the turbid removing toxic substances of employing, blood circulation promoting and blood stasis dispelling way treat.
Specific to Chinese medicine of the present invention, its prescription mechanism is as follows:
Monarch drug: Herba Taraxaci, Herba Violae, Pseudobulbus Cremastrae Seu Pleiones merit are with detoxification and promoting urination.
Ministerial drug: Radix Scutellariae, Cortex Phellodendri merit are with heat clearing and damp drying, eliminating fire and detoxication.Rhizoma Dioscoreae Septemlobae, Herba Hyperici Japonici merit are dispelled turbid with dampness removing, heat-clearing and toxic substances removing; Semen Alpiniae Katsumadai, Fructus Amomi, Fructus Tsaoko fragrance are warded off turbid, removing dampness circulation of qi promoting, and kind turbid damp of controlling stops up stagnant middle Jiao.Rhizoma Atractylodis, Rhizoma Atractylodis Macrocephalae merit are with dampness diuretic, and air making-up and spleen enlivening, temper is good for, transporting officials, then turbid poison is from dispelling.
Adjuvant drug: Hirudo, Tabanus merit are with removing blood stasis Xiao Disorder.
Make medicine: Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.
We's compatibility is reasonable, all medicines share the effect of the turbid removing toxic substances of playing altogether, blood circulation promoting and blood stasis dispelling, the etiology and pathogenesis of the chronic atrophic gastritis that links closely gastric precancerous lesion, patient's gastric mucosa congestion, edema, erosion can be alleviated, alleviate the gastroscope signs such as the white phase of mucosa, grain growth, improve the cure rate of patient's precancerous lesion pathology.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but does not therefore limit the present invention.
Embodiment 1
Treat a Chinese medicine for precancerous lesions of chronic atrophic gastritis, each crude drug weight proportion is as follows:
Herba Taraxaci 15g, Herba Violae 15g, Pseudobulbus Cremastrae Seu Pleiones 6g, Radix Scutellariae 12g, Cortex Phellodendri 12g, Rhizoma Dioscoreae Septemlobae 12g, Herba Hyperici Japonici 15g, Semen Alpiniae Katsumadai 12g, Fructus Amomi 12g, Fructus Tsaoko 9g, Rhizoma Atractylodis 12g, Rhizoma Atractylodis Macrocephalae 12g, Hirudo 2g, Tabanus 2g, Radix Glycyrrhizae 6g.
Embodiment 2
Treat a Chinese medicine for precancerous lesions of chronic atrophic gastritis, each crude drug weight proportion is as follows:
Herba Taraxaci 13g, Herba Violae 17g, Pseudobulbus Cremastrae Seu Pleiones 5g, Radix Scutellariae 10g, Cortex Phellodendri 14g, Rhizoma Dioscoreae Septemlobae 10g, Herba Hyperici Japonici 17g, Semen Alpiniae Katsumadai 10g, Fructus Amomi 14g, Fructus Tsaoko 7g, Rhizoma Atractylodis 14g, Rhizoma Atractylodis Macrocephalae 10g, Hirudo 1.5g, Tabanus 2.5g, Radix Glycyrrhizae 7g.
Embodiment 3
Treat a Chinese medicine for precancerous lesions of chronic atrophic gastritis, each crude drug weight proportion is as follows:
Herba Taraxaci 17g, Herba Violae 13g, Pseudobulbus Cremastrae Seu Pleiones 7g, Radix Scutellariae 14g, Cortex Phellodendri 10g, Rhizoma Dioscoreae Septemlobae 14g, Herba Hyperici Japonici 13g, Semen Alpiniae Katsumadai 14g, Fructus Amomi 10g, Fructus Tsaoko 11g, Rhizoma Atractylodis 10g, Rhizoma Atractylodis Macrocephalae 14g, Hirudo 2.5g, Tabanus 1.5g, Radix Glycyrrhizae 5g.
Embodiment 4
Treat a Chinese medicine for precancerous lesions of chronic atrophic gastritis, each crude drug weight proportion is as follows:
Herba Taraxaci 11g, Herba Violae 19g, Pseudobulbus Cremastrae Seu Pleiones 4g, Radix Scutellariae 8g, Cortex Phellodendri 16g, Rhizoma Dioscoreae Septemlobae 8g, Herba Hyperici Japonici 19g, Semen Alpiniae Katsumadai 8g, Fructus Amomi 16g, Fructus Tsaoko 5g, Rhizoma Atractylodis 16g, Rhizoma Atractylodis Macrocephalae 8g, Hirudo 1g, Tabanus 3g, Radix Glycyrrhizae 8g.
Embodiment 5
Treat a Chinese medicine for precancerous lesions of chronic atrophic gastritis, each crude drug weight proportion is as follows:
Herba Taraxaci 19g, Herba Violae 11g, Pseudobulbus Cremastrae Seu Pleiones 8g, Radix Scutellariae 16g, Cortex Phellodendri 8g, Rhizoma Dioscoreae Septemlobae 16g, Herba Hyperici Japonici 11g, Semen Alpiniae Katsumadai 16g, Fructus Amomi 8g, Fructus Tsaoko 13g, Rhizoma Atractylodis 8g, Rhizoma Atractylodis Macrocephalae 16g, Hirudo 1g, Tabanus 3g, Radix Glycyrrhizae 4g.
Carried out clinical pharrnacokinetics test to treatment precancerous lesions of chronic atrophic gastritis Chinese medicine of the present invention, Details as Follows:
1. data and method
1.1 object of study
Choose in turbid poison accumulate, stomach network blood stasis blocking type precancerous lesions of chronic atrophic gastritis patient 200 example.
1.1.1 diagnostic criteria
The standard that chronic atrophic gastritis diagnostic criteria is formulated with reference to " disease for digest branch of Chinese Medical Association Chinese National Consensus on Chronic Gastritis ".
1.1.2 Gastroscope Diagnosis
CAG Gastroscope Diagnosis foundation: mucosa is red and white, with Bai Weizhu, flatten even disappearance, mucosa exposed vessel, mucosa of duplicature is graininess or nodal-like.As with bile reflux, erosion, mucosa internal hemorrhage etc., be described as atrophic gastritis accompanied bile reflux, erosion, mucosa internal hemorrhage etc.
Under gastroscope, atrophic gastritis has two types, i.e. simple atrophy gastritis and atrophic gastritis accompanied hypertrophy.Simple atrophy gastritis main manifestations is that mucosa is red and white, and with Bai Weizhu, pleat flattens and even disappears, exposed vessel; Atrophic gastritis accompanied hypertrophy main manifestations is mucosa is graininess or nodositas.
1.1.3 the pathological diagnosis of atrophy
With reference to " 2006 chronic gastritis Shanghai common recognition ", as long as pathological diagnosis standard is decided to be the biopsy of chronic gastritis pathology show intrinsic body of gland atrophy, can atrophic gastritis be diagnosed as, and no matter the atrophy block number of biopsy specimen and degree.Clinicist according to pathological examination and in conjunction with gastroscope finding, can finally make the judgement of atrophy scope and degree.
(1) atrophy: atrophy refers to that proper gastric glands body reduces, and is divided into two types: change natural disposition atrophy: intestinal or the raw body of gland of false pylorusization substitute proper gastric glands; Non-ization natural disposition atrophy: refer to that fiber or fibromuscular tissues substitute proper gastric glands, or intrinsic body of gland causes quantity to reduce because of inflammatory cell infiltration.Reduce each 1/3 with proper gastric glands and calculate atrophy degree.Slight: to reduce the intrinsic body of gland number being no more than original body of gland 1/3; Moderate: the intrinsic body of gland number reducing the 1/3-2/3 between original body of gland; Severe: reduce by more than 2/3 intrinsic body of gland number, only residual minority body of gland, disappears even completely.The intestinal that mucous layer occurs lymph follicle and is only limitted to gastric pits region does not include atrophy, need decide according to the body of gland concrete condition of its peripheral region.Body of gland quantity reduce be attributable to all cause glutinous
The pathological process of membrane damage, the body of gland quantity taking from ulcer edge as biopsy reduces, and is exactly not necessarily atrophy.According to mucous layer body of gland size and density and stromal reaction situation, specimen sampling crosses the shallow person that do not reach at muscularis mucosae can infer whether atrophy exists, and adds shallow mark of drawing materials simultaneously, remind and only supply doctor's clinical reference.
(2) intestinal epithelial metaplasia
Slight: intestinal epithelial metaplasia district accounts for body of gland and the superficial epithelium gross area less than 1/3;
Moderate: intestinal epithelial metaplasia district accounts for the l/3-2/3 of body of gland and the superficial epithelium gross area;
Severe: intestinal epithelial metaplasia district accounts for more than 2/3 of body of gland and the superficial epithelium gross area.
(3) atypical hyperplasia (intraepithelial neoplasia)
Have time atypical hyperplasia (intraepithelial neoplasia) and will indicate, point slight and severe (or low level and high-level) two-stage.
Slight: atypical hyperplasia (intraepithelial neoplasia) appears in gastric mucosa structure and epithelial cell, but atypia is very slight, is benign certainly.
1. glandular tube structure is in slightly irregular, and shape is not whole, tortuous, arrangement disorder and density inequality.
2. regenerative atypical hyperplasia (intraepithelial neoplasia) is only limitted to mucosa superficial part, and crypts type then sees mucosa deep layer.
3. at gastric pattern, its epithelial cell is high column, remaining mucous secretions in kytoplasm, even in store normal state.At visible peristalsis visible intestinal peristalsis, then goblet cell reduces.
4. core ellipsoid or shaft-like, volume increases, engrain.
5. nuclear arrangement comparatively dense, is positioned at the bottom of cell based.The difference of slight atypical hyperplasia (intraepithelial neoplasia) and Simple hyperplasia is that the latter is only the hypertrophy of gastric pits and neck of gland portion epithelium and glandular tube extends, but arrangement is still neatly, with mucous membrane surface roughly in vertical state.Epithelial cell differentiation and maturation, without atypia.Simple hyperplasia is common in atrophy companion hyperplastic gastritis.
Severe: structure and cell atypia clearly or judge that optimum pernicious difficult person all belongs to this level, in the stomach specimen or Gastric mucosa biopsy specimen of excision, are usually difficult to differentiate with differentiated minimum cancer.
1. glandular tube structure is obviously disorderly, and the form of glandular tube and size are not whole, can see " back-to-back " or " altogether wall " phenomenon, also show branch or " sprouting " phenomenon.
2. if stove, the normal indention in surface.
3. mucosa holostrome is usually reached, not necessarily the remaining cryptomere expansion glandular tube having deep.
4. epithelial cell is high column (visible peristalsis visible intestinal peristalsis) or Cubic, indefinite form (gastric pattern), and the former is not
See goblet cell or paneth's cell, the latter's secretory function disappears.
5. core ratio increases, and dense dye or loose netted, kernel is obvious.
1.1.4 tcm diagnosis standard
The standard that tcm diagnosis is formulated with reference to " chronic atrophic gastritis Chinese traditional medical diagnose National Consensus ".
Names of disease of tcm
CAG clinical with gastralgia, glutted, painful abdominal mass is vexed, belch, indigestion and loss of appetite etc. for main manifestations, belong to the category such as the traditional Chinese medical science " stomachache ", " feeling of fullness ", " stomach painful abdominal mass ", " stuffy sensation of deftciency type ", " noisy ".Be wherein primary symptom person with gastralgia, belong to " stomachache " category; Vexed for primary symptom person with gastral cavilty distension painful abdominal mass, belong to " feeling of fullness ", " stomach painful abdominal mass " or " stuffy sensation of deftciency type " category; With " emptiness of the stomach discomfort, like the non-pain of pain, like hungry non-famine, seemingly swollen non-swollen, cannot be described " be main manifestations person, genus " noisy " category.
Syndrome-classification standard
The TCM syndrome diagnostic criteria of chronic atrophic gastritis precancerosis feculence poison card is divided into syndrome of dampness-heat of spleen and stomach (primary symptom: gastral cavilty distension, distending pain, bitter taste, nausea and vomiting, red tongue, yellow and greasy fur.Secondary disease: gastral cavilty is scorching hot, halitosis, yellowish urine, uncomfortable in chest, slippery and rapid pulse); Stomach network blood stasis symptom (primary symptom: gastral cavilty distension, twinge, sore spot tenderness, localized pain, dimly red tongue or have petechia, ecchymosis.Secondary disease: melena, complexion is secretly stagnant, stringy and hesitant pulse).Possess above two card primary symptoms two symptoms and time disease two symptoms to be in turbid poison and to accumulate card.
1.1.5 inclusive criteria
(1) patient volunteers tested and can partner;
(2) meet above-mentioned Western medicine diagnose standard, Chinese medical discrimination is for belonging to the person that accumulates pattern of syndrome in turbid poison;
(3) age person between 20 ~ 76 years old, the course of disease 3 ~ 20 years persons;
Do not take all stomach medicines in (4) 2 weeks, within 24 hours, do not drink or surfeit maror.
1.1.6 exclusion standard
(1) all merging peptic ulcers, gastric mucosa have severe dysplasia or pathological diagnosis to be suspected to have the person of cancerating;
(2) severe primary disease, the psychotics such as the heart, brain, liver, kidney and hemopoietic system is merged;
(3) gestation and age of sucking patient.
1.1.7 case is rejected, and comes off and stops test standard
(1) do not meet inclusive criteria after including in, or do not press the case of test determination medication, need rejecting be given.
(2) include case in serious adverse events to occur, develops complications and should not continue reception test, exit or do not complete the whole course for the treatment of voluntarily and affect the treatment or safety judge case, all should be considered as coming off.
(3) person should stop test to occur serious adverse reaction in clinical trial.
(4) occur severe complication or the state of an illness rapidly deterioration person should stop test.
1.2 method
1.2.1 Therapeutic Method
Adopt the Chinese medicine of the embodiment of the present invention 1, under after Herba Taraxaci 15g, Herba Violae 15g, Pseudobulbus Cremastrae Seu Pleiones 6g, Radix Scutellariae 12g, Cortex Phellodendri 12g, Rhizoma Dioscoreae Septemlobae 12g, Herba Hyperici Japonici 15g, Semen Alpiniae Katsumadai 12g, Fructus Amomi 12g(), Fructus Tsaoko 9g, Rhizoma Atractylodis 12g, Rhizoma Atractylodis Macrocephalae 12g, Hirudo 2g, Tabanus 2g, Radix Glycyrrhizae 6g.Be decocted in water for oral dose, day potion, sooner or later sub-service was a course for the treatment of with 2 months.
1.2.2 observation index
Before and after treatment, two groups operate by experienced full-time doctor, carry out gastroscope inspection by full-time doctor, and sign under its scope of itemized record, and in each biopsy tissue in gastric antrum size bending moment pylorus about 2 ~ 4cm place one piece, biopsy 10% formaldehyde is fixed.
Blood, urine, feces routine and the heart, Liver and kidney function inspection is done before and after safety indexes treatment.And record various untoward reaction process and result, analyze reason, judge.
1.2.3 curative effect determinate standard
(1) efficacy assessment standard of clinical efficacy canonical reference in November, 1989 CAIM's digestive system Professional Committee formulation.
Recovery from illness: clinical symptoms, sign disappear, gastroscope check mucosa chronic inflammatory disease is clearly better and reaches slightly, and histopathologic examination confirms body of gland atrophy, and intestinal epithelial metaplasia and dysplasia recover normal or disappear.
Effective: clinical cardinal symptom, sign disappear, gastroscope check mucosa chronic inflammatory disease takes a turn for the better, and histopathologic examination confirms that body of gland atrophy, intestinal epithelial metaplasia and dysplasia recover normal or alleviate 2 level degree
Effective: cardinal symptom, sign obviously alleviate, gastroscope check non-cancer lesion range shorter more than 1/2, histopathologic examination confirms that chronic inflammatory disease alleviates more than 1 level degree, and body of gland atrophy, intestinal epithelial metaplasia and dysplasia alleviate.
Invalid: not reach above-mentioned effective standard or deterioration person.
(2) gastroscopy effect evaluation criterion
Using white for mucosa mutually or piebaldism, blood vessel are shown in thoroughly, pleat low flat, mucosa is coarse, intestinal tuberosity, rotten to the corn as inspection target.Give classification tax point by visual simulation point system to above each variable, each variable is divided into nothing, slight, moderate, severe 4 grades, scores respectively by 0,3,6,9.
Recovery from illness: total mark minimizing is greater than 95%;
Effective: total mark minimizing is greater than 80%;
Effective: total mark minimizing is greater than 30%;
Invalid: symptom total mark reduces less than 30% or increases the weight of.
(3) pathology the standard of curative effect evaluation
Using atrophy, intestinal, atypical hyperplasia (intraepithelial neoplasia) as paper examines index:
These parameters all disappears for recovery from illness;
These parameters is clearly better as effective;
These parameters is good to some extent to be transferred to effectively;
These parameters is unchanged is invalid
1.2.4 statistical method
Adopt spss16.0 version software to carry out statistical analysis, measurement data adopts t inspection, and p<0.05 is that difference has statistical significance.
2. result
2.1 clinical efficacy
200 routine patient clinical curative effects: 122 examples of fully recovering (61.0%), effective 66 examples (33.0%), effective 10 examples (5.0%), invalid 2 examples (1.0%), cure rate 61.0%, total obvious effective rate 94.0%, total effective rate 99.0%.
2.2 gastroscopy effect
200 routine patient clinical curative effects: 124 examples of fully recovering (62.0%), effective 62 examples (31.0%), effective 10 examples (5.0%), invalid 4 examples (2.0%), cure rate 62.0%, total obvious effective rate 93.0%, total effective rate 98.0%.
2.3 pathology curative effects
200 routine patient clinical curative effects: 120 examples of fully recovering (60.0%), effective 60 examples (30.0%), effective 14 examples (7.0%), invalid 6 examples (3.0%), cure rate 60.0%, total obvious effective rate 90.0%, total effective rate 97.0%.
2.4 safety
Do not find obvious adverse reaction, safety is better.
Claims (3)
1. treat a Chinese medicine for precancerous lesions of chronic atrophic gastritis, be made up of the raw material of Chinese medicine medicine of following weight portion:
Herba Taraxaci 11-19 part, Herba Violae 11-19 part, Pseudobulbus Cremastrae Seu Pleiones 4-8 part, Radix Scutellariae 8-16 part, Cortex Phellodendri 8-16 part, Rhizoma Dioscoreae Septemlobae 8-16 part, Herba Hyperici Japonici 11-19 part, Semen Alpiniae Katsumadai 8-16 part, Fructus Amomi 8-16 part, Fructus Tsaoko 5-13 part, Rhizoma Atractylodis 8-16 part, Rhizoma Atractylodis Macrocephalae 8-16 part, Hirudo 1-3 part, Tabanus 1-3 part, Radix Glycyrrhizae 4-8 part.
2. the Chinese medicine for the treatment of precancerous lesions of chronic atrophic gastritis according to claim 1, is characterized in that, is made up of the raw material of Chinese medicine medicine of following weight portion:
Herba Taraxaci 13-17 part, Herba Violae 13-17 part, Pseudobulbus Cremastrae Seu Pleiones 5-7 part, Radix Scutellariae 10-14 part, Cortex Phellodendri 10-14 part, Rhizoma Dioscoreae Septemlobae 10-14 part, Herba Hyperici Japonici 13-17 part, Semen Alpiniae Katsumadai 10-14 part, Fructus Amomi 10-14 part, Fructus Tsaoko 7-11 part, Rhizoma Atractylodis 10-14 part, Rhizoma Atractylodis Macrocephalae 10-14 part, Hirudo 1.5-2.5 part, Tabanus 1.5-2.5 part, Radix Glycyrrhizae 5-7 part.
3. the Chinese medicine for the treatment of treatment precancerous lesions of chronic atrophic gastritis according to claim 2, is characterized in that, be made up of the raw material of Chinese medicine medicine of following weight portion:
Herba Taraxaci 15 parts, Herba Violae 15 parts, Pseudobulbus Cremastrae Seu Pleiones 6 parts, Radix Scutellariae 12 parts, Cortex Phellodendri 12 parts of, Rhizoma Dioscoreae Septemlobae 12 parts, Herba Hyperici Japonici 15 parts, Semen Alpiniae Katsumadai 12 parts, Fructus Amomi 12 parts, Fructus Tsaoko 9 parts, Rhizoma Atractylodis 12 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, Hirudo 2 parts, Tabanus 2 parts, 6 parts, Radix Glycyrrhizae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510358811.3A CN104873880A (en) | 2015-06-26 | 2015-06-26 | Traditional Chinese medicine for treating chronic atrophic gastritis precancerous lesions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510358811.3A CN104873880A (en) | 2015-06-26 | 2015-06-26 | Traditional Chinese medicine for treating chronic atrophic gastritis precancerous lesions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104873880A true CN104873880A (en) | 2015-09-02 |
Family
ID=53941735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510358811.3A Pending CN104873880A (en) | 2015-06-26 | 2015-06-26 | Traditional Chinese medicine for treating chronic atrophic gastritis precancerous lesions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104873880A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112107662A (en) * | 2020-09-21 | 2020-12-22 | 河北省中医院 | Traditional Chinese medicine composition for treating chronic gastritis and precancerous lesions of gastric cancer and medicament and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1727000A (en) * | 2005-07-27 | 2006-02-01 | 赵旭 | Chinese materia medica preparation for treating gastric disease |
| CN1981860A (en) * | 2005-12-16 | 2007-06-20 | 佛山德众药业有限公司 | Chinese-medicinal composition for treating chronic gastritis and atrophic gastritis and its production |
| WO2011079349A1 (en) * | 2009-12-31 | 2011-07-07 | Okada Medical Services Pty Ltd | Okadaella gastrococcus and cancer |
-
2015
- 2015-06-26 CN CN201510358811.3A patent/CN104873880A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1727000A (en) * | 2005-07-27 | 2006-02-01 | 赵旭 | Chinese materia medica preparation for treating gastric disease |
| CN1981860A (en) * | 2005-12-16 | 2007-06-20 | 佛山德众药业有限公司 | Chinese-medicinal composition for treating chronic gastritis and atrophic gastritis and its production |
| WO2011079349A1 (en) * | 2009-12-31 | 2011-07-07 | Okada Medical Services Pty Ltd | Okadaella gastrococcus and cancer |
Non-Patent Citations (2)
| Title |
|---|
| 余志坚: "抗萎防癌汤治疗慢性萎缩性胃炎癌前病变的临床观察", 《内蒙古中医药》 * |
| 洪文旭等: "千金胃肠宁治疗慢性胃炎180例观察", 《实用中医药杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112107662A (en) * | 2020-09-21 | 2020-12-22 | 河北省中医院 | Traditional Chinese medicine composition for treating chronic gastritis and precancerous lesions of gastric cancer and medicament and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100421725C (en) | Chinese medicine composition for treating gastritis and preparing method thereof | |
| CN104352991A (en) | Traditional Chinese medicine preparation for treating gout and preparation method thereof | |
| CN102641454B (en) | Traditional Chinese medicine composition for treating chronic atrophic gastritis | |
| CN113713057B (en) | Traditional Chinese medicine composition and application thereof | |
| CN102552851B (en) | Traditional Chinese medicine for treating chronic gastrointestinal diseases | |
| CN110193050A (en) | Traditional Chinese medicine composition for preventing recurrence and metastasis of digestive tract tumor and preparation method thereof | |
| CN103182059B (en) | Traditional Chinese medicine composition for treating chronic gastritis, and application thereof | |
| CN102423423A (en) | Traditional Chinese medicine for treating urinary tract infection | |
| CN104645202A (en) | Traditional Chinese medicine preparation for treating chronic gastritis | |
| CN104352989A (en) | Medicament composition for treating icterus | |
| CN101637552B (en) | Chinese medicine compound for controlling chronic pelvic inflammation | |
| CN104873880A (en) | Traditional Chinese medicine for treating chronic atrophic gastritis precancerous lesions | |
| CN105832991A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN104688885A (en) | Traditional Chinese medicine for treating acute cholecystitis | |
| CN114632130A (en) | Traditional Chinese medicine composition for treating metaplasia atrophic gastritis | |
| CN105617335A (en) | Radix bupleurum Xianxiong decoction capable of improving bile reflux gastritis after cancer chemoradiotherapy | |
| CN102552767B (en) | Traditional Chinese medicine for treating kidney stone, preparation method and administration mode | |
| CN104436072B (en) | It is a kind of to treat deficiency of both qi and yin, the Chinese medicinal granule of damp and hot blood stasis type chronic atrophic gastritis | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN105853653A (en) | Pharmaceutical composition for treating digestive system disease and preparation method thereof | |
| CN105031023A (en) | Traditional Chinese medicine composition for treating liver cirrhosis portal hypertension | |
| CN104208291A (en) | Chinese medicine preparation for treating heat strangury and preparation method thereof | |
| CN113713073A (en) | Traditional Chinese medicine composition for treating spleen and stomach damp-heat type chronic atrophic gastritis | |
| CN102895396A (en) | Traditional Chinese medicine composition for treating acute urticaria | |
| CN103536831B (en) | The Chinese medicine decoction for the treatment of ulcerative enteritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150902 |
|
| WD01 | Invention patent application deemed withdrawn after publication |